Novo took part in the first round for VectivBio, a short bowel syndrome treatment developer launched out of genetic disease drug developer Therachon.

Switzerland-based rare disease therapy developer VectivBio launched on Tuesday with $35m in capital from investors including pharmaceutical firm Novo.

The corporate joined Inserm Transfer Initiative, the investment arm of research institute Inserm, as well as government-owned investment bank BPIfrance, Cowen Healthcare Investments, Tekla Healthcare Investors, Versant Ventures and OrbiMed in the round.

VectivBio is developing treatments for a range of serious rare diseases. Its lead asset, Apraglutide, targets short bowel syndrome (SBS), which is caused by the physical or functional…